Assessment of potential biomarkers in neuromyelitis optica spectrum disorder


  • Serial, minimally invasive serum glial fibrillary acidic protein (sGFAP) and neurofilament light chain (sNfL) measurement is a feasible and promising means to further characterize and monitor disease activity in patients with neuromyelitis optica spectrum disorder (NMOSD).

Why this matters

  • Noninvasive prognostic markers of NMOSD and differentiating factors from other inflammatory disease, such as multiple sclerosis (MS) are needed.

  • This study provides the foundation for future larger longitudinal studies to establish the prognostic and disease-activity monitoring potential of sGFAP and sNfL in NMOSD.